SEOUL, October 20 (AJP) - South Korea's JW Pharmaceutical said Monday that Hemlibra, its treatment for hemophilia A, has been added to the World Health Organization’s 2025 Essential Medicines List (EML) and the Essential Medicines List for Children (EMLc).
Hemlibra is the only preventive therapy available for both patients with and without inhibitors, offering sustained protection against bleeding through a single subcutaneous injection every four weeks — a major improvement in convenience compared with traditional intravenous infusions.
The WHO’s decision followed an extensive review of Hemlibra’s efficacy, safety, and cost-effectiveness, based on global clinical data evaluated at the request of the World Federation of Hemophilia, the company said.
Clinical trials have shown that the drug helps maintain low annual bleeding rates and significantly reduces joint bleeding, with most side effects limited to mild reactions such as pain at the injection site.
“The WHO listing recognizes Hemlibra’s global clinical value and safety,” JW Pharmaceutical said in a press release. “We will continue working to provide stable and consistent prophylactic treatment for patients in Korea.”
* This article, published by Economic Daily, was translated by AI and edited by AJP.
Copyright ⓒ Aju Press All rights reserved.
